y*****l 发帖数: 5997 | 1 ☆─────────────────────────────────────☆
jhsph07 (银杏 - 愚公) 于 (Mon Dec 20 10:33:35 2010, 美东) 提到:
小生拉潜伏比追涨要放心
VICL明年一季度有个flu swing vaccine的数据(垃圾事件, 不重要), 二季度Ph
III melanoma的database lock(很重要, 可能有提前炒作)。 公司最近刚增发融了
资, 现在的钱可以撑到2012年。
☆─────────────────────────────────────☆
varianinccom (fool) 于 (Mon Dec 20 12:47:17 2010, 美东) 提到:
板凳,记号。
谢谢银杏
☆─────────────────────────────────────☆
MetaIlica (Metallica) 于 (Mon Dec 20 14:30:40 2010, 美东) 提到:
谢银牛,加入watchlist瞅瞅
☆─────────────────────────────────────☆
DNMT2009 (giantpanda) 于 (Mon Dec 20 14:58:04 2010, 美东) 提到:
looks good
☆─────────────────────────────────────☆
yesonse (Robin) 于 (Mon Dec 20 18:00:19 2010, 美东) 提到:
水下了!呵呵。
☆─────────────────────────────────────☆
jhsph07 (银杏 - 愚公) 于 (Mon Dec 20 20:14:06 2010, 美东) 提到:
Small biotech, 涨跌个百分之四五十的都不要太放在心上.
☆─────────────────────────────────────☆
seefree (ben) 于 (Mon Dec 20 20:37:26 2010, 美东) 提到:
RPC
是啊,像RPC今天涨个55%就行了。 |
f**********g 发帖数: 2252 | 2 维考公司,和政府合作,开发预治艾滋病毒的疫苗。
其产品包括:
Allovectin - 7,第三阶段临床试验,治疗转移性黑色素瘤的产品。这个很牛X,非2上
映后,国内谈黑色素色变,到医院祛痣的人,比往年翻了好几倍。
TransVax,一二期临床试验,防止移植后病毒复发和疾病。
H5N1流感疫苗,一期临床试验。
H1N1甲流疫苗,临床前试验,早着呢。
CyMVectin,防止孕前和孕期感染,临床前试验,早着呢。
单纯疱疹2型病毒,研究中,没影儿。
欢迎银杏和其他生物专家们补充纠正。 |
y*****e 发帖数: 1449 | 3 技术分析 2.35 是个坎啊,过不了还得回调一下? |
s*****e 发帖数: 1368 | |
g*********1 发帖数: 725 | 5 The flu swing vaccine news is out today!
【在 y*****l 的大作中提到】 : ☆─────────────────────────────────────☆ : jhsph07 (银杏 - 愚公) 于 (Mon Dec 20 10:33:35 2010, 美东) 提到: : 小生拉潜伏比追涨要放心 : VICL明年一季度有个flu swing vaccine的数据(垃圾事件, 不重要), 二季度Ph : III melanoma的database lock(很重要, 可能有提前炒作)。 公司最近刚增发融了 : 资, 现在的钱可以撑到2012年。 : ☆─────────────────────────────────────☆ : varianinccom (fool) 于 (Mon Dec 20 12:47:17 2010, 美东) 提到: : 板凳,记号。 : 谢谢银杏
|
f**********g 发帖数: 2252 | 6 No response yet. Not big news.
http://finance.yahoo.com/news/Vical-and-the-University-of-pz-21
【在 g*********1 的大作中提到】 : The flu swing vaccine news is out today!
|
f**********g 发帖数: 2252 | 7 CEO has 526,000 shares!
7.Vical Inc. (VICL): Vical is a $142 million biopharma engaged in the
development of treatments using its DNA delivery technology. They have a
number of drugs at different stages of development and testing. The stock
traded near $4 in September, but poor results from a clinical trial and a
secondary offering priced at $2.25 cut the legs out of the share price. CEO
Vijay Samant picked up 500 shares on February 4 for $1,000. You have to
wonder why it was even worth the trouble. He currently owns 526,000 shares.
http://seekingalpha.com/article/251438-seven-stocks-with-ceo-bu |
p********e 发帖数: 1960 | 8 Thanks 老房
ER on 10th...although probably doesn't matter much for small bio...I
probably will buy after the ER...
CEO
【在 f**********g 的大作中提到】 : CEO has 526,000 shares! : 7.Vical Inc. (VICL): Vical is a $142 million biopharma engaged in the : development of treatments using its DNA delivery technology. They have a : number of drugs at different stages of development and testing. The stock : traded near $4 in September, but poor results from a clinical trial and a : secondary offering priced at $2.25 cut the legs out of the share price. CEO : Vijay Samant picked up 500 shares on February 4 for $1,000. You have to : wonder why it was even worth the trouble. He currently owns 526,000 shares. : http://seekingalpha.com/article/251438-seven-stocks-with-ceo-bu
|
y*****l 发帖数: 5997 | 9 ☆─────────────────────────────────────☆
jhsph07 (银杏 - 愚公) 于 (Mon Dec 20 10:33:35 2010, 美东) 提到:
小生拉潜伏比追涨要放心
VICL明年一季度有个flu swing vaccine的数据(垃圾事件, 不重要), 二季度Ph
III melanoma的database lock(很重要, 可能有提前炒作)。 公司最近刚增发融了
资, 现在的钱可以撑到2012年。
☆─────────────────────────────────────☆
varianinccom (fool) 于 (Mon Dec 20 12:47:17 2010, 美东) 提到:
板凳,记号。
谢谢银杏
☆─────────────────────────────────────☆
MetaIlica (Metallica) 于 (Mon Dec 20 14:30:40 2010, 美东) 提到:
谢银牛,加入watchlist瞅瞅
☆─────────────────────────────────────☆
DNMT2009 (giantpanda) 于 (Mon Dec 20 14:58:04 2010, 美东) 提到:
looks good
☆─────────────────────────────────────☆
yesonse (Robin) 于 (Mon Dec 20 18:00:19 2010, 美东) 提到:
水下了!呵呵。
☆─────────────────────────────────────☆
jhsph07 (银杏 - 愚公) 于 (Mon Dec 20 20:14:06 2010, 美东) 提到:
Small biotech, 涨跌个百分之四五十的都不要太放在心上.
☆─────────────────────────────────────☆
seefree (ben) 于 (Mon Dec 20 20:37:26 2010, 美东) 提到:
RPC
是啊,像RPC今天涨个55%就行了。 |
f**********g 发帖数: 2252 | 10 维考公司,和政府合作,开发预治艾滋病毒的疫苗。
其产品包括:
Allovectin - 7,第三阶段临床试验,治疗转移性黑色素瘤的产品。这个很牛X,非2上
映后,国内谈黑色素色变,到医院祛痣的人,比往年翻了好几倍。
TransVax,一二期临床试验,防止移植后病毒复发和疾病。
H5N1流感疫苗,一期临床试验。
H1N1甲流疫苗,临床前试验,早着呢。
CyMVectin,防止孕前和孕期感染,临床前试验,早着呢。
单纯疱疹2型病毒,研究中,没影儿。
欢迎银杏和其他生物专家们补充纠正。 |
|
|
y*****e 发帖数: 1449 | 11 技术分析 2.35 是个坎啊,过不了还得回调一下? |
s*****e 发帖数: 1368 | 12 银杏发帖时我就无脑跟了3000股。不翻番不出! |
g*********1 发帖数: 725 | 13 The flu swing vaccine news is out today!
【在 y*****l 的大作中提到】 : ☆─────────────────────────────────────☆ : jhsph07 (银杏 - 愚公) 于 (Mon Dec 20 10:33:35 2010, 美东) 提到: : 小生拉潜伏比追涨要放心 : VICL明年一季度有个flu swing vaccine的数据(垃圾事件, 不重要), 二季度Ph : III melanoma的database lock(很重要, 可能有提前炒作)。 公司最近刚增发融了 : 资, 现在的钱可以撑到2012年。 : ☆─────────────────────────────────────☆ : varianinccom (fool) 于 (Mon Dec 20 12:47:17 2010, 美东) 提到: : 板凳,记号。 : 谢谢银杏
|
f**********g 发帖数: 2252 | 14 No response yet. Not big news.
http://finance.yahoo.com/news/Vical-and-the-University-of-pz-21
【在 g*********1 的大作中提到】 : The flu swing vaccine news is out today!
|
f**********g 发帖数: 2252 | 15 CEO has 526,000 shares!
7.Vical Inc. (VICL): Vical is a $142 million biopharma engaged in the
development of treatments using its DNA delivery technology. They have a
number of drugs at different stages of development and testing. The stock
traded near $4 in September, but poor results from a clinical trial and a
secondary offering priced at $2.25 cut the legs out of the share price. CEO
Vijay Samant picked up 500 shares on February 4 for $1,000. You have to
wonder why it was even worth the trouble. He currently owns 526,000 shares.
http://seekingalpha.com/article/251438-seven-stocks-with-ceo-bu |
p********e 发帖数: 1960 | 16 Thanks 老房
ER on 10th...although probably doesn't matter much for small bio...I
probably will buy after the ER...
CEO
【在 f**********g 的大作中提到】 : CEO has 526,000 shares! : 7.Vical Inc. (VICL): Vical is a $142 million biopharma engaged in the : development of treatments using its DNA delivery technology. They have a : number of drugs at different stages of development and testing. The stock : traded near $4 in September, but poor results from a clinical trial and a : secondary offering priced at $2.25 cut the legs out of the share price. CEO : Vijay Samant picked up 500 shares on February 4 for $1,000. You have to : wonder why it was even worth the trouble. He currently owns 526,000 shares. : http://seekingalpha.com/article/251438-seven-stocks-with-ceo-bu
|